ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

ClinicalTrials.gov ID: NCT05175105

Public ClinicalTrials.gov record NCT05175105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 26, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused, Followed by a 5-Year Open-label Extension Period

Study identification

NCT ID
NCT05175105
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Enrollment
30 participants

Conditions and interventions

Interventions

  • Mitapivat Drug
  • Mitapivat-matching placebo Drug

Drug

Eligibility (public fields only)

Age range
1 Year to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 5, 2022
Primary completion
Dec 12, 2024
Completion
Dec 31, 2029
Last update posted
Apr 23, 2026

2022 – 2030

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Stanford Medicine Palo Alto California 94304
Children's Hospital Colorado Aurora Colorado 80045
Children's Healthcare of Atlanta - Emory Atlanta Georgia 30322
UChicago Medicine Chicago Illinois 60637
Boston Children's Hospital Boston Massachusetts 02115
Children's Hospital of Michigan Detroit Michigan 48304
Duke University Medical Center Durham North Carolina 27710
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
St Jude's Children's Research Hospital Memphis Tennessee 38105
UT Southwestern Medical Center Dallas Texas 75390
Texas Children's Hospital Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05175105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 23, 2026 · Synced Apr 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05175105 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →